A Phase 1/2 interventional study of Povetacicept in Idiopathic Thrombocytopenic Purpura, Immune Thrombocytopenia and Warm Autoimmune Hemolytic Anemia, sponsored by Alpine Immune Sciences Inc, A Subsidiary of Vertex. Completed at 44 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-14.
Sponsored by Alpine Immune Sciences Inc, A Subsidiary of Vertex (part of Vertex Pharmaceuticals Incorporated) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 110 studies in Purpura, Thrombocytopenic, Idiopathic with a site in United States — 18 open to participants now, 22 under way, 9 of them phase 3. Purpura, Thrombocytopenic, Idiopathic · United States.
Among the 110 studies in Purpura, Thrombocytopenic, Idiopathic with a site in United States, this one is the 59th largest by enrollment of the 94 interventional ones that give a count, is one of 6 that started in 2023, is one of 10 in phase 1/2, and was the 89th registered.
504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.
Browse Purpura, Thrombocytopenic, Idiopathic studies →18 of the 110 studies in Purpura, Thrombocytopenic, Idiopathic with a site in United States are open now. Recruiting first, the newest first:
Amgen · Sites in United States
Ages 18–100
Novartis Pharmaceuticals · Sites in United States
Ages 18+
CRISPR Therapeutics AG · Sites in United States, Germany, Spain
Ages 18+
Incyte Corporation · Sites in United States, Australia, France and 4 more countries
Ages 18+
Novartis Pharmaceuticals · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 103 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (48%) set no upper age limit and 42 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
110 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 25 · Phase 2 43 · Phase 3 33 · Phase 4 2
First in 1999; this study’s year is marked. 6 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 30 is below the median of 58 across 377 interventional studies indexed under Purpura, Thrombocytopenic, Idiopathic.
Median enrollment 42 across the 94 interventional studies, 97 across the 15 observational. Of the 80 that completed or were terminated, 46 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
79 of 110 have an industry lead sponsor. The 10 most frequent:
This study is registered under Alpine Immune Sciences Inc, A Subsidiary of Vertex, one of the names counted as Vertex Pharmaceuticals Incorporated. Under that name alone:
Alpine Immune Sciences Inc, A Subsidiary of Vertex is the lead sponsor of 3 studies on the registry; none are open to participants now.
Vertex Pharmaceuticals Incorporated has 1 study filed under Purpura, Thrombocytopenic, Idiopathic — fewer than ten, so there is no comparison to draw.
9 of the studies in Purpura, Thrombocytopenic, Idiopathic with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07059000Phase 3Kedrion S.p.A.A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP) | 2026-12 |
| NCT04812925Phase 3argenxA Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia | 2027-10 |
| NCT07007962Phase 3SanofiStudy to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment | 2027-11-05 |
| NCT07083960Lakefront Biotherapeutics West LLCOM336 in Autoimmune Cytopenias | 2026-12 |
| NCT07786077Novartis PharmaceuticalsA Study of Patients' Preferences for Primary Immune Thrombocytopenia Treatment | 2026-12-15 |
Add all 9 to your calendar (.ics) → With an account.
Among the 110 studies in Purpura, Thrombocytopenic, Idiopathic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical study is to evaluate povetacicept in adults with autoimmune cytopenias of immune thrombocytopenia, autoimmune hemolytic anemia, and cold agglutinin disease to determine if povetacicept is safe and potentially beneficial in treating these diseases. During the study treatment period participants will receive povetacicept approximately every 4 weeks for 6 months, with the possibility of participating in a 6-month study treatment extension period.
Key Inclusion Criteria:
Indication-specific Criteria
Immune Thrombocytopenia (ITP)
Warm Hemolytic Anemia (wAIHA)
Cold Agglutinin Disease (CAD)
Evidence of hemolysis during screening: (i) indirect bilirubin
>ULN and (ii) lactate dehydrogenase>ULN or haptoglobin \<LLN
Key Exclusion Criteria:
Treatment with any of the following within the noted period prior to study entry
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants grouped in 3 cohorts by diagnosis will be administered Povetacicept.
Drug: Povetacicept
Based on the findings of Part 1, one or two dose levels may be assessed in Part 2; if two dose levels are assessed participants will be randomized to receive one of the two dose levels of Povetacicept.
Drug: Povetacicept
Administered by subcutaneous injection every 4 weeks
Also known as: ALPN-303
Safety and Tolerability as Assessed by Adverse events (AEs) and Serious adverse events (SAEs)
Time frame: Study Day 1 through 30 days after last dose of study drug
Plan to share: No — Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/our-science/clinical-trials-data-sharing/
No publications or documents are linked to this record.
Ran from Jul 2023 to primary completion in Aug 2026, 37 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Povetacicept
Purpura, Thrombocytopenic, Idiopathic →